Condensed Consolidated Statements of Changes in Stockholders' Equity - USD ($)	Total	Securities Purchase Agreement	Series A Convertible Preferred Stock	Common Stock	Common Stock Securities Purchase Agreement	Additional Paid-In Capital	Additional Paid-In Capital Securities Purchase Agreement	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit
Balance at Dec. 31, 2021	$ 10,399,824		$ 24	$ 632		$ 218,730,305		$ 1,894	$ (208,333,031)
Balance, shares at Dec. 31, 2021			23,770	632,340
Stock-based compensation expense	251,214					251,214
Release of restricted stock awards, shares				346
Net share settlement of restricted stock awards	(8,129)					(8,129)
Net share settlement of restricted stock award, shares				(126)
Employee stock purchase plan expense	16,591					16,591
Issuance of common stock		$ 7,108,786			$ 70		$ 7,108,716
Issuance of common stock, shares					69,505
Conversion of Series A convertible preferred stock for common stock			$ (24)	$ 13		11
Conversion of Series A convertible preferred stock for common stock, shares			(23,770)	13,206
Net loss	(6,497,519)								(6,497,519)
Unrealized gain on investments and cash equivalents	0
Foreign currency translation adjustment	(2,293)							(2,293)
Balance at Mar. 31, 2022	11,268,474			$ 715		226,098,708		(399)	(214,830,550)
Balance, shares at Mar. 31, 2022				715,271
Balance at Dec. 31, 2022	5,391,697			$ 2,214		235,314,311		2,679	(229,927,507)
Balance, shares at Dec. 31, 2022				2,213,897
Stock-based compensation expense	129,332					129,332
Release of restricted stock awards, shares				312
Net share settlement of restricted stock awards	(215)					(215)
Net share settlement of restricted stock award, shares				(54)
Employee stock purchase plan expense	7,776					7,776
Issuance of common stock		$ (511)					$ (511)
Cash in lieu of fractional shares, shares				(78)
Cash in lieu of fractional shares	(640)					(640)
Net loss	(5,054,772)								(5,054,772)
Unrealized gain on investments and cash equivalents	1,055							1,055
Foreign currency translation adjustment	780							780
Balance at Mar. 31, 2023	$ 474,502			$ 2,214		$ 235,450,053		$ 4,514	$ (234,982,279)
Balance, shares at Mar. 31, 2023				2,214,077